Top Page
Camurus AB
(OTC:CAMX)
Camurus AB (CAMX) vs. iShares MSCI Sweden ETF (EWD)
Camurus AB Business Overview & Revenue Model
Camurus AB Earnings Call Summary
Camurus AB Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 1.87B | 1.72B | 956.34M | 600.57M | 336.00M | Gross Profit |
| 1.74B | 1.59B | 853.08M | 515.22M | 300.71M | EBIT |
| 469.17M | 532.36M | 71.96M | -112.36M | -206.57M | EBITDA |
| 568.24M | 562.54M | 87.59M | -97.72M | -196.58M | Net Income Common Stockholders |
| 428.39M | 431.44M | 55.55M | -90.45M | -167.26M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 2.85B | 1.19B | 565.54M | 411.57M | 461.79M | Total Assets |
| 3.76B | 1.91B | 1.31B | 1.08B | 1.04B | Total Debt |
| 17.04M | 24.51M | 26.22M | 25.66M | 25.48M | Net Debt |
| -2.84B | -1.17B | -539.32M | -385.92M | -436.31M | Total Liabilities |
| 467.33M | 414.82M | 310.82M | 232.99M | 196.66M | Stockholders Equity |
| 3.29B | 1.49B | 994.67M | 848.91M | 847.44M |
| Cash Flow | Free Cash Flow | |||
| 358.62M | 596.75M | 99.29M | -148.37M | -242.16M | Operating Cash Flow |
| 387.99M | 606.88M | 101.20M | -143.43M | -238.83M | Investing Cash Flow |
| -29.37M | -10.13M | 5.38M | -4.94M | -3.33M | Financing Cash Flow |
| 1.30B | 28.76M | 43.70M | 98.90M | 347.85M |
Camurus AB Technical Analysis
Camurus AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | kr37.59B | 68.37 | 17.31% | ― | 11.69% | 15.57% | |
61 Neutral | kr17.72B | 19.74 | 60.96% | ― | 501.62% | ― | |
54 Neutral | $5.24B | 3.27 | -45.39% | 2.80% | 16.77% | -0.07% | |
48 Neutral | kr916.47M | ― | -48.22% | ― | ― | 67.70% | |
48 Neutral | kr395.31M | ― | -47.73% | ― | 45.52% | 93.35% | |
47 Neutral | kr1.16B | ― | -42.24% | ― | ― | -19.44% | |
42 Neutral | kr1.64B | ― | ― | 9.53% | 41.19% |
Camurus AB Corporate Events
Camurus has entered a collaboration and license agreement with Eli Lilly, granting Lilly exclusive rights to develop and commercialize long-acting incretin products for cardiometabolic health using Camurus’ FluidCrystal technology. This partnership could bring Camurus up to $870 million in milestone payments and royalties, enhancing its market presence in the rapidly expanding field of metabolic diseases while allowing it to maintain its focus on CNS and rare diseases.
The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.
Camurus’ Board of Directors has exercised its authorization to repurchase shares as part of its commitment to the Performance Share Plan 2025/2028. This strategic move involves the repurchase and conversion of 240,000 series C shares into common shares, effectively doubling the company’s holdings of common shares to 480,000, which is expected to enhance the company’s operational flexibility and shareholder value.
The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.
Camurus AB held its annual general meeting where key resolutions were passed, including the re-election of board members and the election of new members, as well as the approval of fees for board and committee members. The meeting also authorized the board to issue new shares and convertibles, acquire and transfer the company’s own shares, and implement a Performance Share Plan for employees. These resolutions aim to enhance Camurus’ strategic flexibility and align employee incentives with company performance, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.
Camurus reported a strong first quarter in 2025, with total revenues increasing by 43% to SEK 558 million and product sales rising by 33% to SEK 485 million. The company also saw a significant 162% rise in profit before tax. Key developments included regulatory approval for Buvidal in Serbia and new launches in Switzerland and Luxembourg, along with the initiation of a Phase 1 clinical study for a new semaglutide depot. The positive CHMP opinion for Oczyesa® in the EU marks a significant advancement for Camurus, potentially enhancing its market positioning and stakeholder value.
The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK750.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.
Camurus has appointed Anders Vadsholt as its new Chief Financial Officer, effective July 1, 2025. Vadsholt brings significant financial and M&A experience from the biotech and pharmaceutical sectors, having previously served as CFO for Orphazyme A/S and Topotarget A/S. This strategic appointment is expected to support Camurus’ continued growth and diversification, enhancing its position in the biopharmaceutical industry. The transition is set to be smooth, with outgoing CFO Jon Garay Alonso remaining until August to facilitate the change.
The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.